Abstract:Neuroprotection, defined as safeguarding neurons from damage and death by inhibiting diverse pathological mechanisms, continues to be a promising approach for managing a range of central nervous system (CNS) disorders, including acute conditions such as ischemic stroke and traumatic brain injury (TBI) and chronic neurodegenerative diseases like Parkinson's disease (PD), Alzheimer's disease (AD), and multiple sclerosis (MS). These pathophysiological conditions involve excessive glutamatergic (Glu) transmission activity, which can lead to excitotoxicity. Inhibiting this excessive Glu transmission has been proposed as a potential therapeutic strategy for treating the CNS disorders mentioned. In particular, ligands of G protein-coupled receptors (GPCRs), including metabotropic glutamatergic receptors (mGluRs), have been recognized as promising options for inhibiting excessive Glu transmission. This review discusses the complex interactions of mGlu receptors with their subtypes, including the formation of homo- and heterodimers, which may vary in function and pharmacology depending on their protomer composition. Understanding these intricate details of mGlu receptor structure and function enhances researchers' ability to develop targeted pharmacological interventions, potentially offering new therapeutic avenues for neurological and psychiatric disorders. This review also summarizes the current knowledge of the neuroprotective potential of ligands targeting group III mGluRs in preclinical cellular (in vitro) and animal (in vivo) models of ischemic stroke, TBI, PD, AD, and MS. In recent years, experiments have shown that compounds, especially those activating mGlu4 or mGlu7 receptors, exhibit protective effects in experimental ischemia models. The discovery of allosteric ligands for specific mGluR subtypes has led to reports suggesting that group III mGluRs may be promising targets for neuroprotective therapy in PD (mGlu4R), TBI (mGlu7R), and MS (mGlu8R).

Recent Advances in the Medicinal Chemistry of Group Ii and Group Iii Mglu Receptors

Dynamics and Modulation of Metabotropic Glutamate Receptors.

Glutamate-regulated Behavior, Transmitter Release, Gene Expression and Addictive Plasticity in the Striatum: Roles of Metabotropic Glutamate Receptors

Molecular Recognition of Metabotropic Glutamate Receptor Type 1 (mglur1): Synergistic Understanding with Free Energy Perturbation and Linear Response Modeling

Group 1 Metabotropic Glutamate Receptors in Neurological and Psychiatric Diseases: Mechanisms and Prospective

SAR Studies on Mglu<sub>5</sub> Receptor Positive Allosteric Modulators (2003- 2013)

Structural basis of positive allosteric modulation of metabotropic glutamate receptor activation and internalization

Synthesis and pharmacological characterization of conformationally restricted 2-amino-Adipic acid analogs and carboxycyclopropyl glycines as selective metabotropic glutamate 2 receptor agonists

SAR studies on mGlu5 receptor positive allosteric modulators (2003- 2013).

Phosphorylation of group I metabotropic glutamate receptors (mGluR1/5) in vitro and in vivo.

Subtype-selective Mechanisms of Negative Allosteric Modulators Binding to Group I Metabotropic Glutamate Receptors

Research Progress of Selective Mglur1 Antagonists

Discovery of GluN2A Subtype-Selective N-methyl-d-aspartate (NMDA) Receptor Ligands

mGlu4R, mGlu7R, and mGlu8R allosteric modulation for treating acute and chronic neurodegenerative disorders

Synthesis and Pharmacological Characterization of 4-Substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: Identification of New Potent and Selective Metabotropic Glutamate 2/3 Receptor Agonists.

On the Origin of the 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylate Scaffold's Unique Group II Selectivity for the Mglu Receptors

Unique Pharmacology of mGluR homo- and heterodimers

Insights into the Structural Aspects of the Mglu Receptor Orthosteric Binding Site

Negative allosteric modulator of Group Ⅰ mGluRs: Recent advances and therapeutic perspective for neuropathic pain

Concerted Conformational Changes Control Metabotropic Glutamate Receptor Activity.